Initiating HIV therapy: Timing is critical, controversial

Postgraduate Medicine

Volumn 115, Issue 2, 2004, Pages 15-26

  Volberding, Paul A ^a,b,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^c S Francisco Vet Aff Med Center   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; ZALCITABINE; ZIDOVUDINE;

COMBINATION CHEMOTHERAPY; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MONITORING; DRUG POTENCY; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; IMMUNOPATHOLOGY; INSULIN RESISTANCE; LIPOATROPHY; LOW DRUG DOSE; LYMPHOCYTE COUNT; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; MITOCHONDRIAL TOXICITY; NEUROTOXICITY; OPPORTUNISTIC INFECTION; PATIENT ATTITUDE; PRACTICE GUIDELINE; RASH; REVIEW; SIDE EFFECT; T LYMPHOCYTE; TREATMENT INDICATION; VIRUS LOAD; VIVID DREAM; CD4 LYMPHOCYTE COUNT; DRUG COMBINATION; HIV INFECTIONS; IMMUNOLOGY; RISK FACTOR; TIME;

ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; PROTEASE INHIBITORS; RISK FACTORS; TIME FACTORS; VIRAL LOAD;

EID: 1342346703     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.2004.02.1441     Document Type: Review

References (17)

1. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000;342(13): 921-9
2. Cahn P, Raffi F, Saag M, et al. Virologic efficacy and patterns of resistance mutations in ART-naive patients receiving combination therapy with once-daily emtricitabine compared to twice-daily stavudine in a randomized, double-blind, multicenter clinical trial. (Abstr 606) Presented at the 10th Conference on Retroviruses and Opportunistic Infections, Feb 10-14, 2003, Boston
3. Staszewski S, Gallant JE, Pozniak AL, et al. Efficacy and safety of tenofovir DF (TDF) versus stavudine (d4T) when used in combination with lamivudine and efavirenz in antiretroviral naïve patients: 96-week preliminary interim results. (Abstr 564b) Presented at the 10th Conference on Retroviruses and Opportunistic Infections, Feb 10-14, 2003, Boston
4. Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999;13(6):F35-43
5. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131(2):81-7
6. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001;286(20):2568-77
7. Sterling TR, Chaisson RE, Bartlett JG, et al. CD4+ lymphocyte level is better than HIV-1 plasma viral load in determining when to initiate HAART. (Abstr 519) Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Feb 4, 2001, Chicago
8. Phair JP, Mellors JW, Detels R, et al. Virologic and immunologic values allowing safe deferral of antiretroviral therapy. AIDS 2002; 16(18):2455-9
9. Dybul M, Fauci AS, Bartlett JG, et al; Panel on Clinical Practices for Treatment of HIV. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med 2002;137(5 Pt 2):381-433
10. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002;288(2):222-35 [Erratum, JAMA 2003;11(1):321
11. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002;288(2):222-35 [Erratum, JAMA 2003;11(1):321
12. Valdez H, Connick E, Smith KY, et al; AIDS Clinical Trials Group Protocol 375 Team. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002;16(14):1859-66
13. Landay AL, Bettendorf D, Chan E, et al. Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease. AIDS Res Hum Retroviruses 2002;18(2):95-102
14. Jacobson MA, Schrier R, McCune JM, et al. Cytomegalovirus (CMV)-specific CD4+ T lymphocyte immune function in long-term survivors of AIDS-related CMV end-organ disease who are receiving potent antiretroviral therapy. J Infect Dis 2001;183(9):1399-404
15. Lilleri D, Piccinini G, Baldanti F, et al. Multiple relapses of human cytomegalovirus retinitis during HAART in an AIDS patient with reconstitution of CD4+ T cell count in the absence of HCMV-specific CD4+ T cell response. J Clin Virol 2003;26(1):95-100
16. Jacobson MA. Human immunodeficiency virus-associated immune reconstitution disease. Am J Med 2001;110(8):662-3
17. DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000;133(6): 447-54